Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/04/10/2860550/0/en/ViGeneron-Announces-First-Patient-Dosed-in-Phase-1b-Clinical-Trial-of-VG901-for-the-Intravitreal-Treatment-of-Retinitis-Pigmentosa.html
https://www.globenewswire.com//news-release/2023/10/25/2766475/0/en/Nature-Communications-publication-reveals-highly-efficient-AAV-delivery-of-large-genes-using-ViGeneron-s-REVeRT-technology.html
https://www.biospectrumasia.com/news/26/20202/vigeneron-daiichi-sankyo-to-develop-novel-gene-therapy-for-prevalent-eye-diseases.html
https://www.pharmatimes.com/news/vigeneron_and_daiichi_sankyo_to_develop_therapy_for_eye_diseases_1447608
https://www.globenewswire.com/news-release/2022/04/26/2428712/0/en/ViGeneron-announces-follow-on-collaboration-with-Daiichi-Sankyo-to-develop-a-novel-gene-therapy-for-prevalent-eye-diseases.html
https://www.globenewswire.com/news-release/2022/04/06/2417228/0/en/ViGeneron-signs-gene-therapy-strategic-collaboration-and-option-agreement-with-Regeneron-for-one-inherited-retinal-disease-target.html